DAFNA Capital Management’s Adicet Bio ACET Stock Holding History

DAFNA Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$811K	Hold	93,812	–	–	0.15%	67
2026 Q1	$639K	Hold	93,812	–	–	0.15%	72
2025 Q4	$790K	Buy	+93,812	New	+$1.04M	0.18%	64
2025 Q3	–	Sell	-33,750	Closed	-$329K	–	76
2025 Q2	$329K	Sell	33,750 -3,750	-10%	-$39.5K	0.09%	69
2025 Q1	$453K	Hold	37,500	–	–	0.13%	73
2024 Q4	$577K	Hold	37,500	–	–	0.15%	71
2024 Q3	$864K	Hold	37,500	–	–	0.2%	64
2024 Q2	$726K	Hold	37,500	–	–	0.17%	67
2024 Q1	$1.41M	Buy	+37,500	New	+$1.55M	0.32%	54
2023 Q4	–	Sell	-49,816	Closed	-$1.09M	–	77
2023 Q3	$1.09M	Hold	49,816	–	–	0.34%	54
2023 Q2	$1.94M	Hold	49,816	–	–	0.53%	41
2023 Q1	$4.59M	Buy	49,816 +10,344	+26%	+$1.3M	1.38%	26
2022 Q4	$5.65M	Sell	39,472 -19,013	-33%	-$4.74M	1.59%	18
2022 Q3	$13.3M	Hold	58,485	–	–	3.58%	7
2022 Q2	$13.7M	Buy	58,485 +13,743	+31%	+$3.02M	3.72%	4
2022 Q1	$14.3M	Sell	44,742 -1,081	-2%	-$249K	3.73%	5
2021 Q4	$12.8M	Buy	45,823 +22,305	+95%	+$3.83M	3.22%	4
2021 Q3	$2.95M	Hold	23,518	–	–	0.78%	31
2021 Q2	$3.87M	Sell	23,518 -549	-2%	-$112K	0.81%	31
2021 Q1	$5.04M	Buy	24,067 +19,218	+396%	+$4.41M	1.2%	24
2020 Q4	$1.09M	Buy	4,849 +625	+15%	+$128K	0.32%	57
2020 Q3	$803K	Buy	+4,224	New	+$1.07M	0.26%	59

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

DAFNA Capital Management's ACET Position: Q2 2026 in Review

DAFNA Capital Management held its Adicet Bio (ACET) position steady in Q2 2026 at 93,812 shares worth $811K. The position accounts for 0.15% of the portfolio, ranked #67.

DAFNA Capital Management first reported a position in ACET in Q3 2020 and has held it in 22 quarters since. The position peaked at $14.3M in Q1 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

DAFNA Capital Management held 93,812 shares of Adicet Bio worth $811K as of Q2 2026.
DAFNA Capital Management left its Adicet Bio share count unchanged in Q2 2026.
Adicet Bio made up 0.15% of DAFNA Capital Management's portfolio in Q2 2026, its #67 holding.
DAFNA Capital Management first reported a position in Adicet Bio in Q3 2020 and has held it in 22 quarters since.
DAFNA Capital Management's Adicet Bio position peaked at $14.3M in Q1 2022.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.